.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Practical Perspectives on Acute Lymphocytic Leukemia

EP. 1: Acute Lymphoblastic Leukemia: Risk Stratification

January 30th 2018

EP. 2: T-Cell Acute Lymphoblastic Leukemia: Impacting Prognosis

January 30th 2018

EP. 3: Philadelphia Chromosome-Positive ALL: Upfront Approaches

January 30th 2018

EP. 4: Defining Ponatinib's Role in Ph-Positive ALL

January 30th 2018

EP. 5: Up-front Approaches to Treating Ph-Negative ALL

January 30th 2018

EP. 6: Optimizing Allogeneic Transplant Strategies in ALL

January 30th 2018

EP. 7: Importance of MRD Testing in Acute Lymphoblastic Leukemia

January 30th 2018

EP. 8: MRD Testing in ALL: Sensitivity and Availability

January 30th 2018

EP. 9: Acute Lymphoblastic Leukemia: Challenges in MRD Testing

January 30th 2018

EP. 10: Acute Lymphoblastic Leukemia: Optimizing MRD Testing

January 30th 2018

EP. 11: ALL: Therapy for Post-Induction MRD-Positivity

January 30th 2018

EP. 12: MRD-Positive ALL: Personal Approaches to Treatment

January 30th 2018

EP. 13: Approaching Treatment for Relapsed/Refractory ALL

January 30th 2018

EP. 14: Relapsed/Refractory ALL: Evaluating Novel Agents

January 30th 2018

EP. 15: Relapsed/Refractory ALL: Inotuzumab Ozogamicin

January 30th 2018

EP. 16: Role of CAR T-Cell Therapy in Relapsed/Refractory ALL

January 30th 2018

EP. 17: Acute Lymphoblastic Leukemia: The Future of Treatment

January 30th 2018